Drug Trial Radar · NCT07169552
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
Dec 30, 2026
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- HC Biopharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)
Conditions
- NSCLC
Interventions
HC010Drug
HC010 Q3W intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 24months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.